PAINLESS Trial Launches Home-Based Brain Stimulation Study for Cancer Pain Management

Cancer-related pain (search)Search disease affects 44.5% of patients and remains one of the most feared symptoms despite advances in oncological care. The PAINLESS study, funded by Horizon Europe (search)Search term, represents the largest multicenter randomized controlled trial to date examining home-based transcranial electrical stimulation (tES) for persistent cancer-related pain management.

Revolutionary Home-Based Approach

The international trial will enroll 450 cancer patients across seven study sites in five countries, including Spain, Germany, Israel, and Switzerland. Unlike traditional clinic-based treatments, participants will self-administer or receive caregiver-assisted tES sessions in their homes for 15 consecutive days, making treatment more accessible for mobility-limited patients.

"Through a home-based approach both for tES as well as for daily clinical monitoring, we expect to reduce the direct and indirect healthcare and social costs, while improving the access to healthcare using e-health tools," the researchers stated in their protocol.

Triple-Blind Design with Advanced Technology

The study employs a sophisticated triple-blind design where patients, clinicians, and data analysts remain unaware of treatment assignments. Participants are randomized in a 2:2:1 ratio to receive:

• Anodal transcranial direct current stimulation (tDCS) over the left primary motor cortex at 2 mA
• 10 Hz transcranial alternating current stimulation (tACS) over the dorsolateral prefrontal cortex at 2 mA
• Sham stimulation as placebo control

The DC-STIMULATOR MOBILE device (neuroConn GmbH (search)Search term) with proprietary headgear enables complete blinding while allowing remote supervision through the PAINLESS platform. Each 20-minute session is monitored and authorized remotely by researchers.

Comprehensive Pain Assessment Strategy

The primary outcome measures cancer pain intensity using an 11-point numerical rating scale, recorded daily for 45 days total (15 days pre-treatment, during treatment, and post-treatment). Secondary outcomes include pain unpleasantness, interference with daily activities, quality of life measures, fatigue, sleep quality, and medication consumption.

"The reproducibility and cross-cultural validity of the NRS have been shown in chronic cancer-related pain (search)Search disease, making it a reliable measure for pain assessment as a clinical outcome," according to the study protocol.

Mechanistic Insights Through Advanced Neurophysiology

A unique strength of PAINLESS lies in its exploration of underlying mechanisms through quantitative sensory testing (QST) and electroencephalography (EEG). The QST protocol includes:

• Thermal pain and detection thresholds
• Temporal summation of pain (TSP) to assess central sensitization
• Conditioned pain modulation (CPM) measuring descending inhibition
• Offset analgesia paradigms
• Contact heat-evoked potentials (CHEPs) concurrent with EEG

"Around 50% of studies in a systematic review reported sensory abnormities using thermal detection thresholds and abnormal thermal pain processing using thermal pain threshold in cancer pain," the researchers noted, highlighting the need for comprehensive sensory evaluation.

Targeting Diverse Cancer Pain Populations

The study includes patients aged 18-75 with lung, breast, pancreatic, or colon cancer (search)Search disease experiencing pain intensity ≥5 on a 0-10 scale for over one month. Unlike previous trials focusing on specific pain causes, PAINLESS embraces heterogeneity, including treatment-related pain, neuropathic pain (search)Search disease, and pain from cancer itself.

"The involvement of a heterogeneous patient group aims to provide a more comprehensive picture of the benefits and drawbacks of therapies as they are used in clinical practice," the protocol states.

Evidence-Based Treatment Rationale

Previous studies support the approach: patients with hepatocellular carcinoma (search)Search disease receiving 10 anodal M1View drug details-tDCS sessions reported reduced pain lasting up to one month post-treatment. In advanced head and neck cancer (search)Search disease, 20 tDCS sessions produced significant pain relief with associated improvements in dysphagia and weight loss symptoms.

A recent meta-analysis showed anodal tDCS over M1View drug details, left DLPFC (search)Search target, or insula areas effectively reduced pain intensity in surgical cancer patients compared to sham, with greater effectiveness in patients with higher baseline pain intensity.

Personalized Medicine Potential

The study aims to identify treatment responders based on ≥30% pain reduction and characterize them using clinical variables and neurophysiological biomarkers. Tree-based algorithms will develop decision rules for predicting treatment outcomes, potentially enabling personalized neuromodulation strategies.

"This will aid clinicians in making decisions on whether the tES therapy is likely to work in a patient and, if so, help them to determine the expected degree of pain relief," researchers explained.

Addressing Clinical Challenges

Current cancer pain management relies heavily on opioids (search)Search drug, frequently leading to medication abuse, dependence, and addiction. The European Society for Medical Oncology (search)Search term recommends multimodal approaches comprising antitumor therapy, analgesic treatment, and non-pharmacological interventions.

"Despite the remarkable improvement in the detection and survival rate among different types of cancer patients in the last decades, cancer pain management remains a clinical challenge," the study authors noted.

Future Implications

If successful, PAINLESS could validate a safe, non-invasive therapeutic tool circumventing many limitations of drug-based analgesia. The home-based protocol particularly benefits immunocompromised or mobility-restricted populations by reducing hospital visits and associated burdens.

The trial's emphasis on mechanistic understanding through EEG and QST biomarkers could enable precision medicine approaches, maximizing analgesic efficacy while minimizing unnecessary interventions. Results may also inform treatments for other chronic pain (search)Search disease conditions characterized by dysregulated central pain processing.